Somaxon Pharmaceuticals

Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription drugs to treat significant medical conditions with unmet medical needs and/or high patient dissatisfaction. The company currently focuses on licensing, developing, and marketing proprietary products and late-stage product candidates for diseases and conditions in the central nervous system (CNS) therapeutic area. Somaxon is currently promoting Silenor, the first and only non-scheduled prescription drug approved for the treatment of sleep maintenance insomnia. Silenor is now available by prescription in the United States.